RALOXIFENE GxP Raloxifene hydrochloride 60 mg tablets, blister pack

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

raloxifene hydrochloride, Quantity: 60 mg

Pieejams no:

MedTAS Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

Raloxifene hydrochloride

Zāļu forma:

Tablet, film coated

Kompozīcija:

Excipient Ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; glycine; colloidal anhydrous silica; polysorbate 80; povidone; titanium dioxide; hypromellose; Carnauba Wax; macrogol 400

Ievadīšanas:

Oral

Vienības iepakojumā:

28 tablets

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Produktu pārskats:

Visual Identification: White to off-white, oval, biconvex, film coated tablets with 'C' on one side and '12' on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Autorizācija statuss:

Licence status A

Autorizācija datums:

2014-01-14